Current and emerging treatment options for a patient with a second relapse of Hodgkin’s lymphoma

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Introduction: Hodgkin’s lymphoma (HL) is largely a curable disease with excellent prognosis. The standard of care in patients with relapsed disease has been to try salvage chemotherapy followed by an autologous stem cell transplantation (ASCT). Managing the patients who relapse after ASCT, is challenging. With the approval of targeted therapies such as PD-1 inhibitors, brentuximab vedotin, the outcomes have improved greatly. Areas covered: This review summarizes the current data available on the newer therapies as well as the present strategies used to treat patients with relapsed HL after an autologous stem cell transplantation. Expert commentary: The approval of brentuximab vedotin and PD-L1 inhibitors has ushered in a new era of targeted therapy in HL. There are currently several targeted therapies under investigation, particularly in the setting of relapsed disease. The current challenges faced are how best to integrate these newer therapies into the existing treatment regimens, finding a right combination with minimal toxicities, role of allogenic transplant in the era of targeted therapy.

Original languageEnglish (US)
Pages (from-to)293-300
Number of pages8
JournalExpert Review of Hematology
Issue number4
StatePublished - Apr 3 2018


  • Hodgkins Lymphoma
  • Second relapse
  • allogenic stem cell transplantation
  • brentuximab
  • nivolumab
  • relapsed Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Current and emerging treatment options for a patient with a second relapse of Hodgkin’s lymphoma'. Together they form a unique fingerprint.

Cite this